e12568 Background: The application of genetic signatures can contributes to determine a less toxic treatment in ederly women with luminal biological profile tumors, where toxicity is less tolerated and with a higher risk of fatal outcomes by therapy. The MINDACT study evaluated this population using MammaPrint, but patients over 70 years of age were poorly represented, corresponding only to 0.8% of the patients evaluated (56 of 6693 patients), and only 26 patients with high clinical risk. Objective: The aim of this study was to verify the possibility of de-escalation of systemic treatment with the use of MammaPrint genetic signature in elderly women, comparing the prevalence of data from the MINDACT study population with a cohort of Brazilian patients submitted to the examination (AGEMA-BRA). Methods: Cross-sectional study comparing the prevalence of low and high risk genomic patients in a population with luminal profile breast carcinoma with high clinical risk in MINDACT study populations with a Brazilian cohort older than 70 years, evaluated by the genetic signature MammaPrint, between 2016 and 2020. Descriptive analysis of data with estimation of simple and relative frequencies of variables in relation to low and high risk classification and study populations (AGEMA-BRA and MINDACT). Then, the chi-square test was used to verify the differences between the proportions. To measure the intensity of differences/associations, relative risks (RR) and their 95% confidence intervals (95% CI) were calculated. The tests were considered significant when p <0.05. Results: From a database of 950 patients submitted to MammaPrint analysis from 2016 to 2020. The population older than 70 yo (71-84 yo) at the time of diagnosis was represented by 89 patients (9.4%), all with high clinical risk. Of these patients, 54 (60.7%) corresponded to low genomic risk and 35 (39.3%) at high genomic risk. The comparative analysis between the prevalence of the Brazilian population and the MINDACT study, in which the low genomic risk was 61.5% and the high genomic risk 38.5%, showed no statistical significance (RR 0.98 (0.69-1.39) p= 0.936). Conclusions: The comparative analysis of the prevalence among the results of MammaPrint in the MINDACT study and in a cohort of Brazilian women (AGEMA-BRA) in the population older than 70 years, showed no statistical difference. With the confirmation of MINDACT data in this age group in a three-fold larger cohort (AGEMA-BRA), it is inferable that, although the low representativeness in the studies, the genetic signature MammaPrint can be applied in the elderly woman. Evaluation of outcomes regarding relapse-free survival and overall survival, an ongoing study, is necessary to confirm the data obtained.

Introduction: Breast cancer is the most common malignant neoplasm in women, except for non-melanoma skin tumors, and the population pyramid demonstrates an aging trend in most countries; it is necessary to value the analysis of the therapies used in this population, but elderly, seeking the de-escalation of treatment, mainly reducing the use of chemotherapy drugs. In this context, the application of genetic signatures contributes to determine a less toxic treatment in these women with luminal biological profile tumors, where toxicity is less tolerated and with a higher risk of fatal outcomes by therapy. The MINDACT study evaluated this population using MammaPrint™, but patients over 70 years of age were poorly represented, corresponding only to 0.8% of the patients evaluated (56 of 6693 patients), and only 26 patients with high clinical risk. Objective: The aim of this study was to verify the possibility of de-escalation of systemic treatment with the use of MammaPrint™ genetic signature in elderly women by comparing the prevalence of data from the MINDACT study population with a cohort of Brazilian patients submitted to the examination (AGEMA-BRA). Methods: This is a cross-sectional study comparing the prevalence of low- and high-risk genomic patients in a population with luminal profile breast carcinoma with high clinical risk in MINDACT study populations with a Brazilian cohort older than 70 years, evaluated by the genetic signature MammaPrint™, between 2016 and 2020. This study describes the analysis of data with the estimation of simple and relative frequencies of variables in relation to low- and high-risk classification and study populations (AGEMABRA and MINDACT). Then, the chi-square test was used to verify the differences between the proportions. To measure the intensity of differences/associations, relative risks (RRs) and their 95% confidence intervals were calculated. The tests were considered significant when p <0.05. Results: From a database of 950 patients submitted to MammaPrint™ analysis from 2016 to 2020, 7 were excluded due to incomplete data. The population over 70 years (71–84 years) at the time of diagnosis was represented by 89 patients (9.4%), all with high clinical risk. Of these patients, 54 (60.7%) corresponded to low genomic risk and 35 (39.3%) at high genomic risk. The comparative analysis between the prevalence of the Brazilian population and the MINDACT study, in which the low genomic risk was 61.5% and the high genomic risk was 38.5%, showed no statistical significance (RR 0.98 (0.69–1.39), p=0.936). Conclusion: The comparative analysis of the prevalence among the results of MammaPrint™ in the MINDACT study and in a cohort of Brazilian women (AGEMA-BRA) in the population older than 70 years showed no statistical difference. With the confirmation of MINDACT data in this age group in a threefold larger cohort (AGEMA-BRA), it is inferable that, although the low representativeness in the studies, the genetic signature of MammaPrint™ can be applied in the elderly women. The evaluation of outcomes regarding relapse-free survival and overall survival, an ongoing study, is necessary to confirm the data obtained.

Background: Parkinson’s disease and essential tremor are common diseases that cannot be cured. These diseases cause a major impact on the patients’ lifestyle, and as they are progressive over time, their symptoms tend to get worse as well as these individuals’ quality of life. Objective: To analyze how the duration of the disease impact quality of life and other aspects related to the disease. Methods: A systematic review was carried out, and a meta-analysis developed including original articles published after 2006 that assessed the quality of life of patients with diseases that presented tremor as a symptom. Results: The number of papers found totaled 7.114, out of those, 27 were included in the systematic review, and 15 of them were also included in the meta-analysis. The articles found analyzed sociodemographic, neuropsychiatric scales, and disease severity scales. In the meta-analysis we found that the time of disease impacts the score of PDQ-39 in numbers of dominants, the mini-mental score, and the UPDRS score. Conclusion: Longer time of disease since diagnostic results in a negative impact on the patients’ quality of life, cognition, emotional status, activities of daily living, motor examination, and therapy complication.

RESUMOO uso do selênio (Se) na alimentação humana e animal tem despertado a atenção dos pesquisadores devido ao seu duplo status como nutriente essencial e altamente tóxico (GIERUS, 2007). Diversos estudos apontam o papel do mineral na fertilidade masculina, contudo, não há evidências claras sobre a sua influência na fertilidade feminina. A partir disso, este trabalho objetivou analisar a relação entre o uso de selênio e a reprodução feminina, através de análises do ciclo estral, níveis de FSH e LH, e avaliação da taxa de fecundidade. Neste estudo, 36 ratas foram divididas em 3 grupos, e submetidas às técnicas de lavado vaginal e gavagem com selênio quelado, além de histerectomia total para contagem do número de fetos gerados. A análise dos resultados apontou que não houve influência significativa do selênio na fertilidade e fecundidade das ratas.

- BACKGROUND: Proper fixation of the surgical mesh determines the success of a herniorrhaphy. Understanding the inflammatory response and the mechanical properties of the mesh helps to define whether a fixation method is superior. AIM: This study aimed to evaluate the healing of defects in the abdominal wall of rats, comparing the repair of macroporous polypropylene meshes fixed with surgical glue and polypropylene thread. METHODS: In 20 Wistar rats, a defect was produced in the abdominal wall, with the integrity of the parietal peritoneum. For correction, the meshes were fixed with surgical glue (2-octyl cyanoacrylate) (subgroup C1), or polypropylene suture (subgroup C2). The two subgroups of 10 animals were euthanized on the 90th postoperative day, and the fragments of the abdominal wall were submitted to macroscopic, histological, and tensiometric analysis. RESULTS: Macroscopic analysis did not show any abnormalities. Tensiometry on the 90th postoperative day in subgroup C1 showed mean rupture tension of 28.47N and in subgroup C2 32.06N (p=0.773). The inflammatory process score revealed that both groups are in the subacute phase (p=0.380). CONCLUSION: The fixation of a polypropylene macroporous mesh to repair an abdominal wall defect can be performed with surgical glue (2-octyl cyanoacrylate) or polypropylene suture, both methods being equally effective.